Transcytosis-inducing biomaterials for actively translocating nanomedicines

Lei Xu,Quan Zhou,Shiqun Shao,Youqing Shen

DOI: https://doi.org/10.1016/b978-0-12-822425-0.00021-x

2021-01-01

Abstract:The past three decades have witnessed the tremendous development of nanomedicines in cancer therapy, which aim at improving the efficacy of anticancer agents while decreasing their side effects in normal tissues. However, most of the nanomedicines did not exhibit satisfactory efficacy in preclinical studies due to the biological barriers imposed by the circulation system and tumor lesion. Of particular hindrances is the heterogeneity of the Enhanced Permeability and Retention (EPR) effect across individual patients and tumors as well as the weak intratumoral penetration, which impede nanomedicines’ extravasation into and penetration throughout tumor tissues. Emerging evidences indicate that transcytosis can be exploited to overcome the two major hurdles, enabling the design of actively translocating nanomedicines for active extravasation and infiltration into solid tumors. In this chapter, we summarize the recent progress in the exploration of how the physiochemical properties of cells and nanoparticles influence the active transcytosis of nanomedicines, in hope of resolving the inherent extravasation and infiltration dilemmas of nanomedicines and facilitating the development of clinically efficient nanomedicines.